Quality of Life in Patients with Allergic and Immunologic Skin Diseases: in the Eye of the Beholder

Allergic and immunologic skin diseases negatively impact the quality of life (QoL) of affected patients with detrimental consequences. Nonetheless, in everyday clinical practice the evaluation of QoL is often overlooked. Considering the increasing prevalence of atopic dermatitis, allergic contact dermatitis, hereditary angioedema, cutaneous mastocytosis, and urticaria, it is essential to determine the effects of allergic and immunologic skin diseases on QoL. A joint meeting (GET TOGETHER 2021) of the Italian Society of Allergology, Asthma and Clinical Immunology (SIAAIC) and the Italian Society of Allergological, Occupational and Environmental Dermatology (SIDAPA) aimed to summarize the features of the main QoL tools used in these diseases and to describe the extent of QoL impairment as well as the impact of treatments on QoL, particularly biologic therapies. The assessment of QoL in patients with allergic and immunologic skin diseases relies on generic, organ-specific and disease-specific questionnaires. While generic and organ-specific questionnaires allow comparison between different diseases, disease-specific questionnaires are designed and validated for specific cohorts: the QoL Index for Atopic Dermatitis (QoLIAD) and the Childhood Atopic Dermatitis Impact Scale (CADIS) in atopic dermatitis, the ACD-11 in allergic contact dermatitis, the Angioedema QoL Questionnaire (AE-QoL) and the Hereditary Angioedema QoL questionnaire (HAE-QoL) in hereditary angioedema, the Mastocytosis QoL Questionnaires (MCQoL e MQLQ) in cutaneous mastocytosis, and the Chronic Urticaria QoL questionnaire (CU-Q2oL) in urticaria. Among the many factors that variably contribute to QoL impairment, pruritus can represent the leading cause of patient discomfort. Biologic therapies significantly ameliorate QoL in atopic dermatitis, hereditary angioedema, mastocytosis and chronic urticaria. In general, adequate management strategies are essential for improving QoL in patients with allergic and immunologic skin diseases.

Citing Articles

Burden of Disease and Unmet Needs in the Diagnosis and Management of Atopic Dermatitis in the Arabic Population of the Middle East.

Mahmoud O, Yosipovitch G, Attia E J Clin Med. 2023; 12(14).

PMID: 37510789 PMC: 10380694. DOI: 10.3390/jcm12144675.

Advancing the understanding of allergic contact dermatitis: from pathophysiology to novel therapeutic approaches.

Tramontana M, Hansel K, Bianchi L, Sensini C, Malatesta N, Stingeni L Front Med (Lausanne). 2023; 10:1184289.

PMID: 37283623 PMC: 10239928. DOI: 10.3389/fmed.2023.1184289.

A Study of Efficacy and Safety of Ashwagandha (Withania somnifera) Lotion on Facial Skin in Photoaged Healthy Adults.

Narra K, Naik S, Ghatge A Cureus. 2023; 15(3):e36168.

PMID: 36937128 PMC: 10017910. DOI: 10.7759/cureus.36168.

Therapeutical Targets in Allergic Inflammation.

Salvati L, Liotta F, Annunziato F, Cosmi L Biomedicines. 2022; 10(11).

PMID: 36359393 PMC: 9687898. DOI: 10.3390/biomedicines10112874.

Urticaria.

Kolkhir P, Gimenez-Arnau A, Kulthanan K, Peter J, Metz M, Maurer M Nat Rev Dis Primers. 2022; 8(1):61.

PMID: 36109590 DOI: 10.1038/s41572-022-00389-z.

References

Weller K, Groffik A, Church M, Hawro T, Krause K, Metz M . Development and validation of the Urticaria Control Test: a patient-reported outcome instrument for assessing urticaria control. J Allergy Clin Immunol. 2014; 133(5):1365-72, 1372.e1-6. DOI: 10.1016/j.jaci.2013.12.1076. View

Saini S, Bindslev-Jensen C, Maurer M, Grob J, Bulbul Baskan E, Bradley M . Efficacy and safety of omalizumab in patients with chronic idiopathic/spontaneous urticaria who remain symptomatic on H1 antihistamines: a randomized, placebo-controlled study. J Invest Dermatol. 2014; 135(1):67-75. PMC: 4269803. DOI: 10.1038/jid.2014.306. View

Bennike N, Heisterberg M, White I, Mahler V, Silvestre-Salvador J, Gimenez-Arnau A . Quality of life and disease severity in dermatitis patients with fragrance allergy-A cross-sectional European questionnaire study. Contact Dermatitis. 2019; 81(2):89-96. DOI: 10.1111/cod.13252. View

Lau M, Matheson M, Burgess J, Dharmage S, Nixon R . Disease severity and quality of life in a follow-up study of patients with occupational contact dermatitis. Contact Dermatitis. 2011; 65(3):138-45. DOI: 10.1111/j.1600-0536.2011.01896.x. View

Grattan C, ODonnell B, Francis D, Niimi N, Barlow R, Seed P . Randomized double-blind study of cyclosporin in chronic 'idiopathic' urticaria. Br J Dermatol. 2000; 143(2):365-72. DOI: 10.1046/j.1365-2133.2000.03664.x. View

ODonnell B, Lawlor F, Simpson J, Morgan M, Greaves M . The impact of chronic urticaria on the quality of life. Br J Dermatol. 1997; 136(2):197-201. View

Simonsen A, Sommerlund M, Deleuran M, Mortz C, Johansen J . Course of skin symptoms and quality of life in children referred for patch testing--a long-term follow-up study. Acta Derm Venereol. 2014; 95(2):206-10. DOI: 10.2340/00015555-1911. View

Zuberbier T, Dorr T, Aberer W, Alvaro M, Angier E, Arasi S . Proposal of 0.5 mg of protein/100 g of processed food as threshold for voluntary declaration of food allergen traces in processed food-A first step in an initiative to better inform patients and avoid fatal allergic reactions: A GA²LEN position.... Allergy. 2021; 77(6):1736-1750. DOI: 10.1111/all.15167. View

Saini S, Rosen K, Hsieh H, Wong D, Conner E, Kaplan A . A randomized, placebo-controlled, dose-ranging study of single-dose omalizumab in patients with H1-antihistamine-refractory chronic idiopathic urticaria. J Allergy Clin Immunol. 2011; 128(3):567-73.e1. DOI: 10.1016/j.jaci.2011.06.010. View

10.

Zhao Z, Ji C, Yu W, Meng L, Hawro T, Wei J . Omalizumab for the treatment of chronic spontaneous urticaria: A meta-analysis of randomized clinical trials. J Allergy Clin Immunol. 2016; 137(6):1742-1750.e4. DOI: 10.1016/j.jaci.2015.12.1342. View

11.

Heisterberg M, Menne T, Johansen J . Fragrance allergy and quality of life - development and validation of a disease-specific quality of life instrument. Contact Dermatitis. 2014; 70(2):69-80. View

12.

Anderson R, Rajagopalan R . Development and validation of a quality of life instrument for cutaneous diseases. J Am Acad Dermatol. 1997; 37(1):41-50. DOI: 10.1016/s0190-9622(97)70210-x. View

13.

Reilly M, Lavin P, Kahler K, Pariser D . Validation of the Dermatology Life Quality Index and the Work Productivity and Activity Impairment-Chronic Hand Dermatitis questionnaire in chronic hand dermatitis. J Am Acad Dermatol. 2003; 48(1):128-30. DOI: 10.1067/mjd.2003.128. View

14.

Yagami A, Furue M, Togawa M, Saito A, Hide M . One-year safety and efficacy study of bilastine treatment in Japanese patients with chronic spontaneous urticaria or pruritus associated with skin diseases. J Dermatol. 2016; 44(4):375-385. PMC: 5412823. DOI: 10.1111/1346-8138.13644. View

15.

Nguyen T . Immune-modulation via IgD B-cell receptor suppresses allergic skin inflammation in experimental contact hypersensitivity models despite of a Th2-favoured humoral response. Immunol Lett. 2018; 203:29-39. DOI: 10.1016/j.imlet.2018.09.008. View

16.

Both H, Essink-Bot M, Busschbach J, Nijsten T . Critical review of generic and dermatology-specific health-related quality of life instruments. J Invest Dermatol. 2007; 127(12):2726-39. DOI: 10.1038/sj.jid.5701142. View

17.

Marin-Cabanas I, Berbegal-de Gracia L, de Leon-Marrero F, Hispan P, Silvestre J . Management of Chronic Spontaneous Urticaria in Routine Clinical Practice Following the EAACI/GA(2)LEN/EDF/WAO Guidelines. Actas Dermosifiliogr. 2017; 108(4):346-353. DOI: 10.1016/j.ad.2016.12.012. View

18.

Nettis E, Ferrucci S, Ortoncelli M, Pellacani G, Foti C, Di Leo E . Use of Dupilumab in 543 Adult Patients With Moderate-to-Severe Atopic Dermatitis: A Multicenter, Retrospective Study. J Investig Allergol Clin Immunol. 2020; 32(2):124-132. DOI: 10.18176/jiaci.0641. View

19.

Fricke J, Avila G, Keller T, Weller K, Lau S, Maurer M . Prevalence of chronic urticaria in children and adults across the globe: Systematic review with meta-analysis. Allergy. 2019; 75(2):423-432. DOI: 10.1111/all.14037. View

20.

van Anrooij B, Kluin-Nelemans J, Safy M, Flokstra-de Blok B, Oude Elberink J . Patient-reported disease-specific quality-of-life and symptom severity in systemic mastocytosis. Allergy. 2016; 71(11):1585-1593. DOI: 10.1111/all.12920. View